Covid-19 Updates | T-Cell Immunotherapy Market is projected to grow at an annualized rate of 12.2% by 2030

4
health-fitness

Summary

Driven by high success rates in clinical trials and the potential to confer sustained periods of disease remission, T-cell therapies have received significant financial support, with approved products poised to soon achieve blockbuster status

Press Release

Roots Analysis has announced the addition of “Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition)-Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, NHL, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma and Others), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100 and others), Key Players and Key Regions (North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings.

Know more:  https://www.rootsanalysis.com/reports/view_document/t-cell-therapies-market/261.html

Key Market Insights

Over 975 T-cell candidate therapies are currently approved / under development

CAR-T cell products continue to dominate the clinical / preclinical pipeline, representing 78% of the total number of molecules, followed by TCR (15%) and TIL (7%) based therapies. Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 10% are being evaluated in late clinical stages (phase II and above). Examples of late-stage clinical candidates include bb2121, JCAR017, GSK3377794, IMCgp100 and lifileucel.

 

China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals

In the last 10 years, over 410 clinical trials, evaluating various types of CAR-T cell therapies, were registered across different geographies; interestingly, over 50% of these trials are being conducted in China.

Partnership activity within this domain has grown at a CAGR of 42%, between 2005 and 2020

Since 2005, more than 340 agreements were inked related to T-cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (25%), technology licensing (18%) and product development and commercialization agreements (11%).

Over USD 17 billion has been invested by both private and public investors, across more than 270 instances

It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), initial public offerings (13%) and grants (13%).

North America and Europe are anticipated to capture over 83% of the market share by 2030

With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 12.2% during the next decade. The market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

Get Latest Market Insights:

https://www.rootsanalysis.com/reports/view_document/t-cell-therapies-market/261.html